Please use this identifier to cite or link to this item: https://doi.org/10.11613/BM.2018.010705
Title: Missed detection of significant positive and negative shifts in gentamicin assay: Implications for routine laboratory quality practices
Authors: Koerbin, G
Liu, J 
Eigenstetter, A
Tan, C.H 
Badrick, T
Loh, T.P 
Keywords: gentamicin
gentamicin
Article
drug determination
good laboratory practice
laboratory test
mathematical model
medical society
pathology
quality control
child
false negative result
human
laboratory technique
procedures
standards
Child
Clinical Laboratory Techniques
False Negative Reactions
Gentamicins
Humans
Quality Control
Issue Date: 2018
Publisher: Biochemia Medica, Editorial Office
Citation: Koerbin, G, Liu, J, Eigenstetter, A, Tan, C.H, Badrick, T, Loh, T.P (2018). Missed detection of significant positive and negative shifts in gentamicin assay: Implications for routine laboratory quality practices. Biochemia Medica 28 (1) : 10705. ScholarBank@NUS Repository. https://doi.org/10.11613/BM.2018.010705
Abstract: Introduction: A product recall was issued for the Roche/Hitachi Cobas Gentamicin II assays on 25 th May 2016 in Australia, after a 15 - 20% positive analytical shift was discovered. Laboratories were advised to employ the Thermo Fisher Gentamicin assay as an alternative. Following the reintro-duction of the revised assay on 12 th September 2016, a second reagent recall was made on 20 th March 2017 after the discovery of a 20% negative analytical shift due to erroneous instrument adjustment factor. Materials and methods: The practices of an index laboratory were examined to determine how the analytical shifts evaded detection by routine internal quality control (IQC) and external quality assurance (EQA) systems. The ability of the patient result-based approaches, including moving average (MovAvg) and moving sum of outliers (MovSO) approaches in detecting these shifts were examined. Results: Internal quality control data of the index laboratory were acceptable prior to the product recall. The practice of adjusting IQC target following a change in assay method resulted in the missed negative shift when the revised Roche assay was reintroduced. While the EQA data of the Roche subgroup showed clear negative bias relative to other laboratory methods, the results were considered as possible ‘matrix effect’. The MovAvg method detected the positive shift before the product recall. The MovSO did not detect the negative shift in the index laboratory but did so in another laboratory 5 days before the second product recall. Conclusions: There are gaps in current laboratory quality practices that leave room for analytical errors to evade detection. © Croatian Society of Medical Biochemistry and Laboratory Medicine.
Source Title: Biochemia Medica
URI: https://scholarbank.nus.edu.sg/handle/10635/175128
ISSN: 1330-0962
DOI: 10.11613/BM.2018.010705
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_11613_BM_2018_010705.pdf2.41 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

5
checked on Feb 27, 2021

Page view(s)

26
checked on Feb 26, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.